A California judge has ruled that Biogen owes Roche $124 million in royalties for its use of intellectual property developed more than 40 years ago by the Swiss company’s subsidiary Genentech that covered a process to manufacture monoclonal antibodies. More:
read more
Six new treatments aim to improve patient outcomes across key areas More: Hikma and Celltrion deepen alliance to boost biosimilar access in MENA Source: News
read moreAmgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. More: Amgen unveils DTC platform with 60% discount on Repatha, giving US lowest price
read moreThe company will work with new local contract manufacturers in India to boost supply of its key medicines. More: Eli Lilly earmarks B-plus for contract manufacturing partnerships in India Source: fierce
read moreAstraZeneca and Daiichi Sankyo’s Datroway has become the first cancer drug to show an overall survival benefit against chemotherapy for certain patients with a particularly aggressive form of breast cancer. In a phase 3 trial, the antibody-drug conjugate has scored
read moreMyeloid Therapeutics’ name no longer fits its pipeline. Having expanded beyond the eponymous myeloid cells, the biotech has rebranded as Create Medicines and committed to an R&D strategy that spans in vivo multi-immune programming. More: Myeloid Therapeutics creates new identity
read more© 1994 - 2025 B.M. Pharmaceuticals